41st week of 2013 patent applcation highlights part 42 |
Patent application number | Title | Published |
20130267456 | THERAPEUTIC APPLICATIONS OF SMAD7 - The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis. | 2013-10-10 |
20130267457 | PEPTIDE INHIBITORS OF PROTEIN SYNTHESIS - The present invention discloses compositions of peptide inhibitors of protein synthesis, and methods of identifying peptide inhibitors that are capable of inhibiting protein synthesis through an interaction at a stem-loop H18 in 16S rRNA of a 30S ribosomal subunit. Screening methods for peptides are disclosed, in addition to methods of determining the affinity of a test compound for a ribosomal subunit. | 2013-10-10 |
20130267458 | COMPOSITIONS AND USES OF MATERIALS WITH HIGH ANTIMICROBIAL ACTIVITY AND LOW TOXICITY - Improved synthetic copolypeptide antimicrobials contain cationic amino acid residues and may be based on a blocky sequence. These antimicrobials show low mammalian toxicity and may undergo directed self-assembly. The inventive synthetic copolypeptides are useful in treatment of wounds and other infections. | 2013-10-10 |
20130267459 | Anti-Pathogen Systems - Provided is a system for protecting plants from attack by pests, including pathogens such as fungi. Specifically, a plant defensin is provided in conjunction with a protease inhibitor protects a plant from pest attack or reduces severity of an attack. | 2013-10-10 |
20130267460 | Methods of Inhibiting Alphavirus Replication and Treating Alphavirus Infection - The invention provides methods of inhibiting alphavirus replication and treating alphavirus infection. | 2013-10-10 |
20130267461 | COMPOUNDS AND THERAPEUTIC APPLICATIONS RELATED TO INHIBITION OF DENDRITIC CELL IMMUNORECEPTOR (DCIR) ACTIVITY AND SIGNALING EVENTS - The invention is concerned with methods, compounds and pharmaceutical compositions for interfering dendritic cell immunoreceptor (DCIR) activity and signalling events. Described herein are compounds useful in targeting one or more of intracellular modulators and the uses thereof for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus (HIV) binding, entry and/or replication in human cells. Exemplary compounds include peptides and antisense molecules. | 2013-10-10 |
20130267462 | Lipid Construct for Delivery of Insulin to a Mammal - The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes. | 2013-10-10 |
20130267463 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TH17-MEDIATED DISEASE COMPRISING POLY-GAMMA-GLUTAMIC ACID - Provided are a pharmaceutical use of poly-gamma-glutamic acid used for preventing or treating Th17-mediated diseases, a composition for preventing or treating Th17-mediated diseases comprising poly-gamma-glutamic acid as an active ingredient, and a method of preventing or treating Th17-mediated diseases using the same. The pharmaceutical composition is effective in inhibiting the differentiation of Th17 cells while promoting Treg cells, and, thus, can be useful in preventing or treating Th17-mediated diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, and the like. | 2013-10-10 |
20130267464 | THERAPEUTIC USE OF A GROWTH FACTOR, METRNL - The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects. | 2013-10-10 |
20130267465 | COLLAGENOUS MATERIAL - A process for the manufacture of a collagenous material from a plurality of collagen particles is described. The collagen particles are derived from a natural tissue material, are substantially free of non-fibrous tissue proteins, cellular elements and lipids or lipid residues, and comprise fragments of collagen fibres displaying original collagen fibre architecture and molecular ultrastructure of the natural tissue material. The process comprises the step of freeze drying the collagen particles in suspension in a freeze-drying suspension medium. | 2013-10-10 |
20130267466 | Treatment Of Bleeding With Low Half-Life Fibrinogen - The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable. | 2013-10-10 |
20130267467 | SERINE PROTEASE INHIBITORS - The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the prevention of blood loss, and as components of fibrin adhesives. | 2013-10-10 |
20130267468 | FACTOR VIII GLYCOFORMS - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 2013-10-10 |
20130267469 | IPA AS A THERAPEUTIC AGENT, AS A PROTECTIVE AGENT, AND AS A BIOMARKER OF DISEASE RISK - Indole-3-propionic acid as a marker and for treatment for Huntington Disease. | 2013-10-10 |
20130267470 | Treatment Of Penetrative Injury To The Brain - The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel). | 2013-10-10 |
20130267471 | Formulations and methods of use for alpha connexin C-terminal (ACT) peptides - This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided. | 2013-10-10 |
20130267472 | AQUEOUS OPHTHALMIC SOLUTION BASED ON CYCLOSPORIN - This invention concerns an aqueous ophthalmic solution containing an immunosuppressive agent, such as cyclosporin A, and at least three polymers. The three polymers are preferably a combination of a cellulose derivative, a polyvinyl derivative, and a macrogolglycerol hydroxystearate. | 2013-10-10 |
20130267473 | MANNOSIDASES CAPABLE OF UNCAPPING MANNOSE-1-PHOSPHO-6-MANNOSE LINKAGES AND DEMANNOSYLATING PHOSPHORYLATED N-GLYCANS AND METHODS OF FACILITATING MAMMALIAN CELLULAR UPTAKE OF GLYCOPROTEINS - The invention provides mannosidases capable of uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans, methods of using such mannosidases, glycoproteins produced using the methods, as well as methods of facilitating mammalian cellular uptake of glycoproteins. | 2013-10-10 |
20130267474 | NOVEL PHYTOCHEMICALS FROM EXTRACTS OF MAPLE SYRUPS AND MAPLE TREES AND USES THEREOF - The present invention describes phytochemicals present in maple syrup and maple tree extracts by butanol, ethyl acetate and methanol. Novel compounds are isolated from maple syrups, including one compound Quebecol generated in the maple syrup manufacturing process. Also described are digesting extract of maple syrup. The phytochemicals may be used for the treatment or prevention of cancers, metabolic syndromes, diabetes, microorganism infections and/or antioxidants. | 2013-10-10 |
20130267475 | Method of Treating Neurological Conditions with Oleandrin - A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form. | 2013-10-10 |
20130267476 | Pesticidal Active Mixtures Comprising Pyrazole Compounds - The present invention relates to pesticidal mixtures comprising as active compounds
| 2013-10-10 |
20130267477 | METHOD OF USING NUTRITIONAL COMPOUNDS DIHYDROQUERCETIN (TAXIFOLIN) AND ARABINOGALACTAN IN COMBINATION WITH DIHYDROQUERCETIN (TAXIFOLIN) TO REDUCE AND CONTROL CARDIOMETABOLIC RISK FACTORS ASSOCIATED WITH METABOLIC SYNDROME AND HYPERCHOLESTEROLEMIA - The method of using nutritional compounds including Dihydroquercetin (taxifolin), Arabinogalactan and Arabinogalactan combined with Dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors, associated with metabolic syndrome and hypercholesterolemia in a mammal, specifically a human, resulting in the enhancement of metabolism, reduced control levels of cholesterol and triglycerides, reduced oxidative damage in humans and other health benefits. | 2013-10-10 |
20130267478 | COSMETIC - There is disclosed a cosmetic comprises a sugar compound obtained by reacting a hydroxyl group of a saccharide, an isocyanate group-containing organopolysiloxane represented by the following general formula (1), and an isocyanate group-containing organic compound represented by the following general formula (2). | 2013-10-10 |
20130267479 | Solutions Containing A Boron Complex, Method for Preparing Said Solutions, and Uses of Said Solutions - The present invention relates to solutions including at least one boron complex obtained through the reaction between at least one boron salt, consisting of a borate anion selected from within the group consisting of metaborate anions, tetraborate anions, pentaborate anions, octaborate anions, decaborate anions, and the mixtures thereof, and a cation selected from within the group including sodium cations, potassium cations, ammonium cations, and the mixtures thereof, and at least one polyol and at least one amino compound. The basic boron concentration is greater than 2 wt % of the total weight of the solution. The invention also relates to a method for preparing said solutions and to the uses of said solutions, particularly in the field of agriculture. | 2013-10-10 |
20130267480 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 2013-10-10 |
20130267481 | PHOSPHOLIPID DRUG ANALOGS - Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: | 2013-10-10 |
20130267482 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO - Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed. | 2013-10-10 |
20130267483 | Hydroxy Acid Complexes for Skin Antiaging, Acne, and Skin Whitening - This invention relates to complexes of certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including molybdenum, having a hydroxy acid [HA] and an amino acid [AA] moiety concurrently bound to a single said metal and having a spirocyclic, bidentate chelate structure of formula (I). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation. The said metal complexes are useful for topical conditions that includes dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, age spots, dark circles around eyes, skin pigmentation, topical inflammation, liver spots, pigmented spots, wrinkles, blemishes, skin lines, oily skin, acne, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, disturbed keratinization, dandruff, bacterial infection, fungal infection, wound healing, body odor, and skin changes associated with aging; | 2013-10-10 |
20130267484 | TREATMENT OF RHEUMATOID ARTHRITIS WITH MASITINIB - The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human rheumatoid arthritis. | 2013-10-10 |
20130267485 | Pharmaceutical Combination of Resveratrol and Progestin to Treat and/or Prevent Myoma and/or Endometriosis - The present invention relates to a combination of resveratrol with progestogen, and medicaments and pharmaceutical compositions containing the same, which are useful in the treatment and/or prevention of myoma and/or endometriosis, providing their size reduction and the control of related symptoms. Said association may additionally comprise an estrogen component. A treatment method and a kit are also objects of this invention. | 2013-10-10 |
20130267486 | POLYMERIC TOPICAL COMPOSITIONS - The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions. | 2013-10-10 |
20130267487 | COMPOSITION FOR PREVENTION OF NAUSEA OR VOMITING - Provided is a composition for preventing nausea or vomiting, including a 5-HT | 2013-10-10 |
20130267488 | PHARMACEUTICAL FORMULATION HAVING NEUROPROTECTIVE ACTIVITY - [Problem] The purpose of the present invention is to provide a neuroprotective agent which is capable of effectively protecting intraocular cells including optic nerves and is effective as a composition for ophthalmic membrane staining in cases where removal of an ophthalmic membrane is carried out. | 2013-10-10 |
20130267489 | FULVESTRANT FORMULATIONS - Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C. | 2013-10-10 |
20130267490 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING NANONIZED SILVER SULFADIAZINE AND CHLORHEXIDINE GLUCONATE - The invention relates to an improved topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate; wherein silver sulfadiazine is in nanonized form. | 2013-10-10 |
20130267491 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKKε and/or TBK-1: in which: R | 2013-10-10 |
20130267492 | ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 2013-10-10 |
20130267493 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK - The present invention relates to indole and indazole compounds of Formula (I) | 2013-10-10 |
20130267494 | 1,4-OXAZEPANE DERIVATIVES - Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof. | 2013-10-10 |
20130267495 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2013-10-10 |
20130267496 | IMIDAZOPYRAZINE SYK INHIBITORS - Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. | 2013-10-10 |
20130267497 | KINASE INHIBITORS - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 2013-10-10 |
20130267498 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2013-10-10 |
20130267499 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR | 2013-10-10 |
20130267500 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL - Uses of 5-HT | 2013-10-10 |
20130267501 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof - The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 2013-10-10 |
20130267502 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors - This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents. | 2013-10-10 |
20130267503 | PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY ACID ESTERS - The present invention relates to an injectable, pharmaceutical composition comprising a C | 2013-10-10 |
20130267504 | PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY GLYCEROL ESTERS - The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs. | 2013-10-10 |
20130267505 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZYL ALCOHOL - The present invention relates to a pharmaceutical composition comprising benzyl alcohol and polyoxyethylene derivatives of sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs. | 2013-10-10 |
20130267506 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY - Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog. | 2013-10-10 |
20130267507 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BICYCLIC BENZENE DERIVATIVES - The present invention is concerned with novel antifungal 5,6-dihydro-4H-pyrrolo-[1,2-a][1,4]benzodiazepines and 6H-pyrrolo[1,2-a][1,4]benzodiazepines substituted with bicyclic benzene derivatives of Formula (I) | 2013-10-10 |
20130267508 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS - Benzimidazoles having inhibitory activity on RSV replication and having the formula | 2013-10-10 |
20130267509 | THIAZOLE DERIVATIVES - Method of treating central nervous systems disease by administering | 2013-10-10 |
20130267510 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS - The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders. | 2013-10-10 |
20130267511 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors - The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, | 2013-10-10 |
20130267512 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS - This invention relates to a method of treating and/or preventing endometriosis comprising administering a JNK inhibitor. The JNK inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis. | 2013-10-10 |
20130267513 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 - A compound of formula Ia or formula Ib, or a pharmaceutically acceptable salt or ester thereof, wherein R | 2013-10-10 |
20130267514 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2013-10-10 |
20130267515 | COMBINATION COMPRISING AN ATP ANALOG AND AN ADENOSINE RECEPTOR ANTAGONIST OR A NUCLEOBASE/NUCLEOSIDE ANALOG FOR THE TREATMENT OF CANCER - A method for treating an ATP analog-induced side effect in a subject comprises administering an effective amount of an adenosine receptor antagonist to the subject. A method for treating cancer in a subject comprises administering a nucleobase and/or nucleoside prior to administering an ATP analog. | 2013-10-10 |
20130267516 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS - Compounds of general formula I, (formula [I)], their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds. | 2013-10-10 |
20130267517 | NOVEL 4-METHYL-DIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 2013-10-10 |
20130267518 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS - There are provided according to the invention compounds of formula (I) | 2013-10-10 |
20130267519 | 1,2-PYRIDAZINES, 1,6-PYRIDAZINES AND PYRIMIDINES - This invention relates to novel 1,2-pyridazines, 1,6-pyridazines or pyrimidines of the formula | 2013-10-10 |
20130267520 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS - The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5, Kv4.3, and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general formula (I), where R | 2013-10-10 |
20130267521 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. | 2013-10-10 |
20130267522 | METHODS FOR TREATING CANCER - The invention relates to methods and uses for the treatment of a cancer. In particular, the invention relates to the use of a folate-vinca conjugate to treat urinary bladder cancer (e.g., invasive transitional cell carcinoma (InvTCC)). | 2013-10-10 |
20130267523 | ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH DEPRESSION - Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, 4-HNE, and/or hsCRP) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating at least one symptom (e.g., at least one core symptom) of depression in a subject and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein. | 2013-10-10 |
20130267524 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2013-10-10 |
20130267525 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES - The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. | 2013-10-10 |
20130267526 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2013-10-10 |
20130267527 | SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS - The present invention relates to substituted imidazopyrazine compounds of general formula (I), in which R | 2013-10-10 |
20130267528 | TRANS-EPITHELIAL OSMOTIC COLLYRIUM FOR THE TREATMENT OF KERATOCONUS - Trans-epithelial osmotic collyrium for the treatment of keratoconus by corneal cross-linking with UV rays, of the type consisting of a riboflavin-based solution and an absorption enhancement adjuvant consisting of benzalkonium chloryde (BAC). The solution has a hypoosmolarity degree ranging between −70% and −30% over an isotonic solution and contains a BAC concentration accordingly ranging between 0.005% and 0.035%. | 2013-10-10 |
20130267529 | INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds of the formula I: | 2013-10-10 |
20130267530 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same. | 2013-10-10 |
20130267531 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same. | 2013-10-10 |
20130267532 | CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE - The invention concerns compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein n, R | 2013-10-10 |
20130267533 | 5HT1A AGONISTS FOR TREATMENT OF HIGH CHOLESTEROL - A method of treating and/or lowering elevated cholesterol by administering a therapeutically effective amount of at least one 5HT | 2013-10-10 |
20130267534 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2013-10-10 |
20130267535 | Treatment of Chronic Inflammation with a 1,2,4-Triazolo [1,5a] Pyridine Derivative - This application describes and provides a method of treating diseases or disorders characterized by chronic systemic inflammation, such as rheumatoid arthritis, using a compound that inhibits JAK2 kinase. | 2013-10-10 |
20130267536 | SUBSTITUTED METHYL AMINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS, METHODS FOR PRODUCTION AND USE THEREOF - The present invention relates to novel substituted methyl-amines, serotonin 5-HT | 2013-10-10 |
20130267537 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2013-10-10 |
20130267538 | TREATMENT OF MITOCHONDRIAL DISEASES - The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein. | 2013-10-10 |
20130267539 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2013-10-10 |
20130267540 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-- (TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA - The present application is directed to solid forms of compounds of formula I: | 2013-10-10 |
20130267541 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to fused heterocyclic azaindane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 2013-10-10 |
20130267542 | HISTONE DEACETYLASES (HDACS) INHIBITORS - Histone deacetylases inhibitors (HDACIs) and compositions comprising the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed. | 2013-10-10 |
20130267543 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF - The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity. | 2013-10-10 |
20130267544 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases - The present invention provides compositions and methods useful for treating and preventing ocular diseases by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders such as but not limited to, macular edema, uveitis and diabetic retinopathy. | 2013-10-10 |
20130267545 | METHOD OF IMPROVING PLANT GROWTH BY REDUCING FUNGAL INFECTIONS - A method of improving the growth of plants such as corn, soybean, wheat, or rice is provided by reducing the incidence of one or more fungal infections. The method comprises the step of applying a foliar treatment composition at least once to established plants, wherein the treatment composition comprises effective amounts of active ingredients prothioconazole, trifloxystrobin, and azoxystrobin. | 2013-10-10 |
20130267546 | Multifunctional Radical Quenchers and Their Uses - The present disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof: compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation. | 2013-10-10 |
20130267547 | PRODRUGS UTILIZING A TRANSPORTER-DIRECTED UPTAKE MECHANISM - Prodrugs comprising a lipophilic drug linked to a transport moiety that can be taken up by a fatty acid transporter are provided. The transport moiety comprises a lipid chain connected to a hydrophilic group (e.g. a carboxylic acid, a phosphate, or a sphingosine-like moiety). Due to the presence of the transport moiety, the prodrugs are substrates for endogenous fatty acid transporter systems. The transport moiety thus serves as a carrier or targeting moiety to facilitate uptake of the entire prodrug complex by endogenous fatty acid transporter systems, thereby moving the prodrug into cells and tissues where drug distribution and effects are desired. Hydrolysis of the chemical linkage between the lipid-like moiety and the lipophilic drug releases the drug in an active form within the cells or tissues. | 2013-10-10 |
20130267548 | SUBSTITUTED 6-FLUORO-1H-PYRAZOLO[4,3-B]PYRIDINES AND USE THEREOF - The present application relates to novel substituted 6-fluoro-1H-pyrazolo[4,3-b]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for preparing Medicaments for the treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders. | 2013-10-10 |
20130267549 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis - The invention relates to the use of a pyrimidylaminobenzamides of formula I | 2013-10-10 |
20130267550 | Compounds and Methods for Treating Aberrant Adrenocartical Cell Disorders - Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient. | 2013-10-10 |
20130267551 | SUBSTITUTED HYDROGENATED THIENO-PYRROLO[3,2-C]PYRIDINE, LIGANDS, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR USING THE ABOVE - The present invention relates to novel substituted tetrahydro-4H-thieno-pyrrolo[3,2-c]pyridines of the general formula 1, geometrical isomers, mixtures of geometrical isomers, and pharmaceutically acceptable salts thereof, | 2013-10-10 |
20130267552 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY - This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia. | 2013-10-10 |
20130267553 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 2013-10-10 |
20130267554 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION - The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein. | 2013-10-10 |
20130267555 | INDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - Indoles having inhibitory activity on RSV replication and having the formula I | 2013-10-10 |